GILD
Gilead Sciences Inc
NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$130.84
+1.55% today
Updated 2026-04-29
Market cap
$159.92B
P/E ratio
19.00
P/S ratio
5.43x
EPS (TTM)
$6.78
Dividend yield
2.44%
52W range
$93 – $156
Volume
6.1M
WallStSmart proprietary scores
72
out of 100
Grade: B
Buy
Investment rating
5.3
Growth
C+5.5
Quality
C+9.5
Profitability
A+8.7
Valuation
A6/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$158.36
+21.03%
12-Month target
$138.43
+5.80%
Intrinsic (DCF)
$237.26
Margin of safety
+44.85%
5 Strong Buy18 Buy8 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 28.90% — above average
+ ROE 40.70% — strong efficiency
+ Free cash flow $3.12B — positive
+ 44.85% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $27.28B | $27.12B | $28.75B | $29.44B | $29.44B | $30.8B |
| Net income | $4.59B | $5.67B | $480.00M | $8.51B | $2.18B | — |
| EPS | — | — | — | — | $6.78 | $8.84 |
| Free cash flow | $8.34B | $7.42B | $10.30B | $9.46B | $3.12B | — |
| Profit margin | 16.83% | 20.89% | 1.67% | 28.90% | 28.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | MERCIER, JOHANNA | Sale | 3,000 | $140.96 |
| 2026-04-15 | DICKINSON, ANDREW D | Sale | 3,000 | $140.96 |
| 2026-03-27 | O'DAY, DANIEL PATRICK | Sale | 10,000 | $136.82 |
Peer comparison
Smart narrative
Gilead Sciences Inc trades at $130.84. representing a P/E of 19.00x trailing earnings. Our Smart Value Score of 72/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. TTM revenue stands at $29.44B. with profit margins at 28.90%. Our DCF model estimates intrinsic value at $237.26.
Frequently asked questions
What is Gilead Sciences Inc's stock price?
Gilead Sciences Inc (GILD) trades at $130.84.
Is Gilead Sciences Inc overvalued?
Smart Value Score 72/100 (Grade B, Buy). DCF value $237.26.
What is the price target of Gilead Sciences Inc (GILD)?
The analyst target price is $158.36, representing +21.0% upside from the current price of $130.84.
What is the intrinsic value of Gilead Sciences Inc (GILD)?
Based on our DCF model, intrinsic value is $237.26, a +44.9% margin of safety versus $130.84.
What is the future stock price of GILD by 2030?
Our research-backed model estimates Gilead Sciences Inc could reach $377.22 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Gilead Sciences Inc's revenue?
TTM revenue is $29.44B.
Piotroski F-Score?
6/9 — moderate financial health.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.43x
ROE40.70%
Beta0.40
50D MA$141.16
200D MA$126.58
Shares out1.24B
Float1.24B
Short ratio—
Avg volume6.1M
Performance
1 week-1.20%
1 month-8.17%
3 months-9.24%
YTD+4.97%
1 year—
3 years—
5 years—